Read more
Informationen zum Autor Mark A. Rothstein holds the Herbert F. Boehl Chair of Law and Medicine and is Director of the Institute for Bioethics, Health Policy and Law at the University of Louisville. He has appointments in the Departments of Medicine and Family and Community Medicine at the School of Medicine and at the Louis D. Brandeis School of Law. Professor Rothstein is a leading authority on genetics, privacy, and health policy. He has served as an advisor to the NIH, CDC, DOE, Institute of Medicine, National Conference of State Legislatures, and numerous other public and professional entitles. Klappentext Through analyses of the complex underlying issues, this interdisciplinary volume frames the agenda for dealing with genetic variation and incorporating pharmacogenomics into health care. The three sections of this book, Research Issues, Clinical Issues, and Social Perspectives address key elements integral to a comprehensive discussion of this emerging field.This groundbreaking text...* Examines new research strategies, methodologies, and ethical and social considerations of pharmacogenomics* Addresses practical considerations of anticipated changes in education, training, oversight, guidelines and protocols, and continuing education requirements* Provides analyses of the potential enormous impact of pharmacogenomics, such as in the standard of care and treatment, including perspectives from the fields of anthropology, law, ethics, and economics Zusammenfassung This book examines the ethical, legal, and social implication of pharmacogenomics. Through analyses of the complex underlying issues, this interdisciplinary volume frames the agenda for dealing with genetic variation and incorporating pharmacogenomics into health care. Inhaltsverzeichnis Foreword (F. Collins). Preface. PART I: INTRODUCTION: SCIENCE AND SOCIETY. Public Attitudes About Pharmacogenomics (M. Rothstein, et al. ). Pharmacogenomics: Pharmacology and Toxicology in the Genomics (H. Mohrenweiser). The Implications of Population Genetics for Pharmacogenomics (C. Hanis). PART II: RESEARCH AND DEVELOPMENT CHALLENGES AND CONSIDERATIONS. Genome Research and Minorities (H. Greely). Drug Development Strategies (P. Manasco & T. Arledge). Drug Development, Regulation, and Genetically Guided Therapy Pharmacogenomics (D. Feigal & S. Gutman). Intellectual Property and Commercial Aspects of Pharmacogenomics (A. Nunnally, et al. ). PART III: CLINICAL APPLICATIONS. Integration of Pharmacogenomics into Medical Practice (G. Omenn & A. Motulsky). Clinical Utility Pharmacogenetics and Pharmacogenomics (N. Holtzman). Medical Liability for Pharmacogenomics (L. Palmer). The Challenges of Pharmacogenomics for Pharmacy Education, Practice, and Regulation (D. Brushwood). PART IV: THE SOCIAL DIMENSION. Economic Implications of Pharmacogenomics (C. Reeder & W. Dickson). Pharmacogenomics and the Social Construction of Identity (M. Foster). Pharmacogenomics: Considerations for Communities of Color (L. Nsiah-Jefferson). Constitutional Issues in the Use of Pharmacogenomic Variations Associated with Race (J. Robertson). PART V: EPILOGUE: POLICY PRESCRIPTIONS (M. Rothstein). Pharmacogenomics and Minority Populations: General Population Survey Questionnaire (M. Rothstein). Index. ...
